CN101940751B - Traditional Chinese medicinal preparation for treating sequela of cerebral infarction - Google Patents
Traditional Chinese medicinal preparation for treating sequela of cerebral infarction Download PDFInfo
- Publication number
- CN101940751B CN101940751B CN2010102941016A CN201010294101A CN101940751B CN 101940751 B CN101940751 B CN 101940751B CN 2010102941016 A CN2010102941016 A CN 2010102941016A CN 201010294101 A CN201010294101 A CN 201010294101A CN 101940751 B CN101940751 B CN 101940751B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- cerebral infarction
- rhizoma
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicinal preparation for treating the sequela of cerebral infarction. The traditional Chinese medicinal preparation is prepared from raw astragalus, salvia, angelica, chuanxiong, gastrodia, antelope horn, earthworm, cyathula, red peony, mulberry twig, saposhnikovia, ground pine, spatholobus, silkworm, typhonium, scorpion, pangolin scales, eucommia, agkistrodon, tortoise shell, lyceum, alpinia, turtle shell and licorice which are combined to generate a synergy to effectively nourish Yin and tonify kidney, expel wind, reduce phlegm, tonify Qi, invigorate blood circulation and remove blood stasis. In the traditional Chinese medicinal preparation, the astragalus, salvia, angelica and chuanxiong are used for tonifying Qi, invigorating blood circulation and removing blood stasis; the gastrodia, antelope horn and earthworm are used for reducing phlegm and extinguishing wind, and calming liver and suppressing Yang; and the tortoise shell and turtle shell are salty in flavor and cold in nature, return in the liver channel and have the effects of simultaneously nourishing Yin and suppressing Yang, and tonifying liver and kidney. The traditionalChinese medicinal preparation is used for treating the sequela of cerebral infarction, complied with the theories of traditional Chinese medicine and modern pharmacological study, and has the advantages of remarkable therapeutic effect and suitability for popularization and application.
Description
Technical field
The invention belongs to the Chinese medicine technical field, be specifically related to a kind of Chinese medicine preparation for the treatment of cerebral infarction sequela.
Background technology
The main pathological change of cerebral infarction is on the basis of cerebral arteriosclerosis, form thrombosis in the blood vessel, blocked blood flow, cause ischemia, anoxia and the necrosis of cerebral tissue, make patient hemiplegia, aphasia, side numb limbs and tense tendons, shakiness, gatism, mental disorder, the dementia of walking even become the plant man partially occur, part brain stem infarct and Big Area Cerebral Infarction can be fatal.
Early treatment, early intervention can be improved patient's prognosis, alleviate and minimizing disables.Cerebral infarction sequela is meant in the cerebral infarction morbidity after 1 year, if also there are symptoms such as hemiplegia or aphasis or facial hemiparalysis, just be called cerebral infarction sequela, also be called the cerebral infarction sequela phase this period, compare with convalescent period, resume speed and degree are slower.The general western medical treatment of cerebral infarction adopts thrombolytic, anticoagulant, brain protection, falls fibre, anti-platelet aggregation, can not make but sequela stage has medicine; Though adopt treatment by Chinese herbs such as PIANTAN FUYUAN WAN now, curative effect is still not very good.
Summary of the invention
Therefore people better treat very demand of cerebral infarction sequela Chinese medicine preparation to curative effect, and the inventor has found the Chinese medicine preparation of the treatment cerebral infarction sequela of better efficacy finally through research repeatedly, has finished the present invention.The object of the invention provides little, the treating both the principal and secondary aspects of a disease of a kind of side effect, can more effectively treat the Chinese medicine preparation of cerebral infarction sequela.
The consumption that medicine of the present invention is formed part is that inventor's process gropes to sum up to get for a long time in a large number, and the each component consumption all has curative effect preferably in following weight parts: 1～5 part of Radix Astragali, 1～3 part of Radix Salviae Miltiorrhizae, 0.5～1.5 part of Radix Angelicae Sinensis, 0.5～1.5 part of Rhizoma Chuanxiong, 1～3 part in Rhizoma Gastrodiae, 0.5～1.5 part of Cornu Saigae Tataricae, 1～3 part of Pheretima, 1～3 part of Radix Cyathulae, 1～3 part of Radix Paeoniae Rubra, 0.5～1.5 part of Ramulus Mori, 0.5～1.5 part of Radix Saposhnikoviae, 1～3 part of Herba Lycopodii, 1～3 part of Caulis Spatholobi, 1～3 part of Bombyx Batryticatus, 0.5～1.5 part of Rhizoma Typhonii, 0.5～1.5 part of Scorpio, 0.5～1.5 part of Squama Manis, 1～3 part of the Cortex Eucommiae, 0.5～1.5 part of Agkistrodon, 1～3 part of Carapax et Plastrum Testudinis, 1～3 part of Fructus Lycii, 1～3 part of Fructus Alpiniae Oxyphyllae, 1～3 part of Carapax Trionycis, 0.5～1.5 part in Radix Glycyrrhizae.
Be preferably: 2～4 parts of Radix Astragali, 1.5～2 parts of Radix Salviae Miltiorrhizaes, 0.8～1.2 part of Radix Angelicae Sinensis, 0.8～1.2 part of Rhizoma Chuanxiong, 1.5～2 parts in Rhizoma Gastrodiae, 0.8～1.2 part of Cornu Saigae Tataricae, 1.5～2 parts of Pheretimas, 1.5～2 parts of Radix Cyathulaes, 1.5～2 parts of Radix Paeoniae Rubra, 0.8～1.2 part of Ramulus Mori, 0.8～1.2 part of Radix Saposhnikoviae, 1.5～2 parts of Herba Lycopodiis, 1.5～2 parts of Caulis Spatholobis, 1.5～2 parts of Bombyx Batryticatus, 0.8～1.2 part of Rhizoma Typhonii, 0.8～1.2 part of Scorpio, 0.8～1.2 part of Squama Manis, 1.5～2 parts of the Cortexs Eucommiae, 0.8～1.2 part of Agkistrodon, 1.5～2 parts of Carapax et Plastrum Testudiniss, 1.5～2 parts of Fructus Lycii, 1.5～2 parts of Fructus Alpiniae Oxyphyllaes, 1.5～2 parts of Carapax Trionycis, 0.8～1.2 part in Radix Glycyrrhizae.
More preferably: 3 parts of Radix Astragali, 2 parts of Radix Salviae Miltiorrhizaes, 1 part of Radix Angelicae Sinensis, 1 part of Rhizoma Chuanxiong, 2 parts in Rhizoma Gastrodiae, 1 part of Cornu Saigae Tataricae, 2 parts of Pheretimas, 2 parts of Radix Cyathulaes, 2 parts of Radix Paeoniae Rubra, 1 part of Ramulus Mori, 1 part of Radix Saposhnikoviae, 2 parts of Herba Lycopodiis, 2 parts of Caulis Spatholobis, 2 parts of Bombyx Batryticatus, 1 part of Rhizoma Typhonii, 1 part of Scorpio, 1 part of Squama Manis, 2 parts of the Cortexs Eucommiae, 1 part of Agkistrodon, 2 parts of Carapax et Plastrum Testudiniss, 2 parts of Fructus Lycii, 2 parts of Fructus Alpiniae Oxyphyllaes, 2 parts of Carapax Trionycis, 1 part in Radix Glycyrrhizae.
Improve the cerebral infarction sequela symptom, reduce the effective ways of high relapse rate, should be science diet and master, when passive recovery is taken exercise, by reliable Drug therapy, cerebral infarction inducement atheromatous plaque is formed, and the high basic pathological changes of blood viscosity is effectively treated, and prevents that the arteriosclerosis thrombosis from forming once more; Improve cerebral tissue blood supply oxygen-supplying amount, create a good interior environment for cerebral tissue, recover cerebral nervous system, make the motion by its control, the language nervous system signs improves.Medicine of the present invention is to select the medicine prescription to form on this basis.
Cerebral infarction claims cerebral infarction again, is meant that because brain blood supply obstacle the ischemic gathering of the limitation cerebral tissue that ischemia, anoxia cause etc. make that cerebral blood flow is proud to be reproduced; Side Zhi Xunhuan sets up, and the brain dysbolismus is recovered.Motherland's medical science is included into primary disease " apoplexy " category, empty within its cause of disease is at first blamed (hepatic and renal YIN deficiency is this), the empty reciprocal causation of the wind-fire expectorant stasis of blood and send out primary disease.Therefore in treatment, adopt enriching yin and nourishing kidney, dispelling pathogenic wind and eliminating phlegm, benefiting QI for activating blood circulation blood stasis dispelling treating both the principal and secondary aspects of a disease legislation prescription.The Radix Astragali, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, the blood stasis dispelling of Rhizoma Chuanxiong benefiting QI for activating blood circulation in the present invention, wherein Radix Astragali strongly invigorating primordial QI makes blood circulation depending on qi flow, and modern pharmacological research proves its slow down aging, and the expansion peripheral blood vessel participates in blood pressure regulating, improves the ischemic tissue of brain blood supply; Rhizoma Chuanxiong is the gas medicine in the blood, and the effective ingredient ligustrazine can see through the blood brain barrier expansion of cerebral vascular rapidly, improves cerebral circulation, anticoagulant, and antithrombotic forms; The Radix Salviae Miltiorrhizae stasis of blood of invigorating blood circulation, but anti-cerebral ischemia, antithrombotic, microcirculation improvement promotes tissue repair and regeneration, by the cerebrovascular treatment essential.Rhizoma Gastrodiae, Cornu Saigae Tataricae, Pheretima eliminating phlegm and calming wind, suppressing the hyperactive liver and subsiding YANG, wherein Rhizoma Gastrodiae has been proved to effects such as cranial nerve cell protection, vertigo, blood pressure lowering, convulsion, antiplatelet aggregation, antithrombotics; Cornu Saigae Tataricae, Pheretima have the merit of calm convulsion, antithrombotic.Carapax et Plastrum Testudinis, Carapax Trionycis salty in the mouth are cold in nature, return Liver Channel, and two medicines match and play the merit of nourishing YIN for suppressing the hyperactive YANG, the liver and the kidney tonifying altogether.Medicine of the present invention is used for the treatment of cerebral infarction sequela and meets the traditional Chinese medical science and modern pharmacological research theory, and it is evident in efficacy, is worthy of popularization.
The specific embodiment
Medicine of the present invention is made by following bulk drugs: 1～5 part of Radix Astragali, 1～3 part of Radix Salviae Miltiorrhizae, 0.5～1.5 part of Radix Angelicae Sinensis, 0.5～1.5 part of Rhizoma Chuanxiong, 1～3 part in Rhizoma Gastrodiae, 0.5～1.5 part of Cornu Saigae Tataricae, 1～3 part of Pheretima, 1～3 part of Radix Cyathulae, 1～3 part of Radix Paeoniae Rubra, 0.5～1.5 part of Ramulus Mori, 0.5～1.5 part of Radix Saposhnikoviae, 1～3 part of Herba Lycopodii, 1～3 part of Caulis Spatholobi, 1～3 part of Bombyx Batryticatus, 0.5～1.5 part of Rhizoma Typhonii, 0.5～1.5 part of Scorpio, 0.5～1.5 part of Squama Manis, 1～3 part of the Cortex Eucommiae, 0.5～1.5 part of Agkistrodon, 1～3 part of Carapax et Plastrum Testudinis, 1～3 part of Fructus Lycii, 1～3 part of Fructus Alpiniae Oxyphyllae, 1～3 part of Carapax Trionycis, 0.5～1.5 part in Radix Glycyrrhizae.
Be preferably: 2～4 parts of Radix Astragali, 1.5～2 parts of Radix Salviae Miltiorrhizaes, 0.8～1.2 part of Radix Angelicae Sinensis, 0.8～1.2 part of Rhizoma Chuanxiong, 1.5～2 parts in Rhizoma Gastrodiae, 0.8～1.2 part of Cornu Saigae Tataricae, 1.5～2 parts of Pheretimas, 1.5～2 parts of Radix Cyathulaes, 1.5～2 parts of Radix Paeoniae Rubra, 0.8～1.2 part of Ramulus Mori, 0.8～1.2 part of Radix Saposhnikoviae, 1.5～2 parts of Herba Lycopodiis, 1.5～2 parts of Caulis Spatholobis, 1.5～2 parts of Bombyx Batryticatus, 0.8～1.2 part of Rhizoma Typhonii, 0.8～1.2 part of Scorpio, 0.8～1.2 part of Squama Manis, 1.5～2 parts of the Cortexs Eucommiae, 0.8～1.2 part of Agkistrodon, 1.5～2 parts of Carapax et Plastrum Testudiniss, 1.5～2 parts of Fructus Lycii, 1.5～2 parts of Fructus Alpiniae Oxyphyllaes, 1.5～2 parts of Carapax Trionycis, 0.8～1.2 part in Radix Glycyrrhizae.
Said medicine is fine flour altogether, and processed with honey is ball, and is big as Semen Firmianae, and three times on the one, one time one ball.
The active component of medicine of the present invention can also add various conventional adjuvant required when preparing different dosage form, be prepared into any peroral dosage form commonly used as disintegrating agent, lubricant, binding agent etc. with the method for Chinese medicinal of routine, as: powder, tablet, capsule, oral agents etc.
Embodiment 1: medicine of the present invention is made by following bulk drugs: 1 part of Radix Astragali, 1 part of Radix Salviae Miltiorrhizae, 0.5 part of Radix Angelicae Sinensis, 0.5 part of Rhizoma Chuanxiong, 1 part in Rhizoma Gastrodiae, 0.5 part of Cornu Saigae Tataricae, 1 part of Pheretima, 1 part of Radix Cyathulae, 1 part of Radix Paeoniae Rubra, 0.5 part of Ramulus Mori, 0.5 part of Radix Saposhnikoviae, 1 part of Herba Lycopodii, 1 part of Caulis Spatholobi, 1 part of Bombyx Batryticatus, 0.5 part of Rhizoma Typhonii, 0.5 part of Scorpio, 0.5 part of Squama Manis, 1 part of the Cortex Eucommiae, 0.5 part of Agkistrodon, 1 part of Carapax et Plastrum Testudinis, 1 part of Fructus Lycii, 1 part of Fructus Alpiniae Oxyphyllae, 1 part of Carapax Trionycis, 0.5 part in Radix Glycyrrhizae.
Embodiment 2: medicine of the present invention is made by following bulk drugs: 3 parts of Radix Astragali, 2 parts of Radix Salviae Miltiorrhizaes, 1 part of Radix Angelicae Sinensis, 1 part of Rhizoma Chuanxiong, 2 parts in Rhizoma Gastrodiae, 1 part of Cornu Saigae Tataricae, 2 parts of Pheretimas, 2 parts of Radix Cyathulaes, 2 parts of Radix Paeoniae Rubra, 1 part of Ramulus Mori, 1 part of Radix Saposhnikoviae, 2 parts of Herba Lycopodiis, 2 parts of Caulis Spatholobis, 2 parts of Bombyx Batryticatus, 1 part of Rhizoma Typhonii, 1 part of Scorpio, 1 part of Squama Manis, 2 parts of the Cortexs Eucommiae, 1 part of Agkistrodon, 2 parts of Carapax et Plastrum Testudiniss, 2 parts of Fructus Lycii, 2 parts of Fructus Alpiniae Oxyphyllaes, 2 parts of Carapax Trionycis, 1 part in Radix Glycyrrhizae.
Embodiment 3: medicine of the present invention is made by following bulk drugs: 5 parts of Radix Astragali, 3 parts of Radix Salviae Miltiorrhizaes, 1.5 parts of Radix Angelicae Sinensis, 1.5 parts of Rhizoma Chuanxiongs, 3 parts in Rhizoma Gastrodiae, 1.5 parts of Cornu Saigae Tataricae, 3 parts of Pheretimas, 3 parts of Radix Cyathulaes, 3 parts of Radix Paeoniae Rubra, 1.5 parts of Ramulus Moris, 1.5 parts of Radix Saposhnikoviaes, 3 parts of Herba Lycopodiis, 3 parts of Caulis Spatholobis, 3 parts of Bombyx Batryticatus, 1.5 parts of Rhizoma Typhoniis, 1.5 parts of Scorpios, 1.5 parts of Squama Maniss, shut out 3 parts, 1.5 parts of Agkistrodons, 3 parts of Carapax et Plastrum Testudiniss, 3 parts of Fructus Lycii, 3 parts of Fructus Alpiniae Oxyphyllaes, 3 parts of Carapax Trionycis, 1.5 parts in Radix Glycyrrhizae.
Embodiment 4: medicine of the present invention is made by following bulk drugs: 4 parts of Radix Astragali, 3 parts of Radix Salviae Miltiorrhizaes, 2 parts of Radix Angelicae Sinensis, 0.8 part of Rhizoma Chuanxiong, 3 parts in Rhizoma Gastrodiae, 1 part of Cornu Saigae Tataricae, 1.5 parts of Pheretimas, 3 parts of Radix Cyathulaes, 1 part of Radix Paeoniae Rubra, 0.5 part of Ramulus Mori, 1.5 parts of Radix Saposhnikoviaes, 3 parts of Herba Lycopodiis, 2 parts of Caulis Spatholobis, 2 parts of Bombyx Batryticatus, 1.2 parts of Rhizoma Typhoniis, 0.8 part of Scorpio, 1.5 parts of Squama Maniss, 1.8 parts of the Cortexs Eucommiae, 0.9 part of Agkistrodon, 1 part of Carapax et Plastrum Testudinis, 3 parts of Fructus Lycii, 1.5 parts of Fructus Alpiniae Oxyphyllaes, 1 part of Carapax Trionycis, 0.5 part in Radix Glycyrrhizae.
Embodiment 5: medicine of the present invention is made by following bulk drugs: 5 parts of Radix Astragali, 2 parts of Radix Salviae Miltiorrhizaes, 2 parts of Radix Angelicae Sinensis, 1 part of Rhizoma Chuanxiong, 1 part in Rhizoma Gastrodiae, 1.5 parts of Cornu Saigae Tataricae, 2 parts of Pheretimas, 3 parts of Radix Cyathulaes, 3 parts of Radix Paeoniae Rubra, 0.8 part of Ramulus Mori, 1 part of Radix Saposhnikoviae, 2 parts of Herba Lycopodiis, 3 parts of Caulis Spatholobis, 3 parts of deadlocks, 1.5 parts of Rhizoma Typhoniis, 0.9 part of Scorpio, 0.7 part of Squama Manis, 1 part of the Cortex Eucommiae, 1 part of Agkistrodon, 1 part of Carapax et Plastrum Testudinis, 1.5 parts of Fructus Lycii, 2 parts of Fructus Alpiniae Oxyphyllaes, 2 parts of Carapax Trionycis, 1 part in Radix Glycyrrhizae.
Embodiment 6: medicine of the present invention is made by following bulk drugs: 5 parts of Radix Astragali, 3 parts of Radix Salviae Miltiorrhizaes, 2 parts of Radix Angelicae Sinensis, 1.5 parts of Rhizoma Chuanxiongs, 2 parts in Rhizoma Gastrodiae, 1.5 parts of Cornu Saigae Tataricae, 1 part of Pheretima, 1 part of Radix Cyathulae, 3 parts of Radix Paeoniae Rubra, 1.5 parts of Ramulus Moris, 0.5 part of Radix Saposhnikoviae, 2 parts of Herba Lycopodiis, 1.5 parts of Caulis Spatholobis, 1.5 parts of Bombyx Batryticatus, 0.8 part of Rhizoma Typhonii, 1 part of Scorpio, 1 part of Squama Manis, 2 parts of the Cortexs Eucommiae, 1.5 parts of Agkistrodons, 3 parts of Carapax et Plastrum Testudiniss, 3 parts of Fructus Lycii, 1 part of Fructus Alpiniae Oxyphyllae, 1 part of Carapax Trionycis, 0.5 part in Radix Glycyrrhizae.
Clinical observation material
(1) invention medicine major function and therapeutic domain
1, major function:
Enriching yin and nourishing kidney, dispelling pathogenic wind and eliminating phlegm, benefiting QI for activating blood circulation blood stasis dispelling.
2, therapeutic domain:
Be applicable to cerebral infarction, cerebral infarction sequela, apoplexy sequela.
(2) clinical observation of medicine of the present invention
Treatment group Drug therapy of the present invention, matched group hemiparalysis restoration pill for curing.Therapeutic outcome: treatment is organized in 171 examples, and 34 examples of fully recovering account for 19.9%; Marked improvement 39 examples account for 22.8%; Progressive 59 examples account for 34.5%; Invalid 39 examples account for 22.8%; Total effective rate is 77.2%.Recovery from illness 18 examples account for 11.0% in matched group 164 examples; Marked improvement 26 examples account for 15.9%; Progressive 43 examples account for 26.2%; Invalid 77 examples account for 47%; Total effective rate is 53%.Two groups of total effective rates compare P＜0.01, and there were significant differences.
Table 1 liang group curative effect relatively
| Group | The example number | Recovery from illness | Produce effects | Progressive | Invalid | Total effective rate |
| Treatment group (medicine of the present invention) | 171 | 34 | 39 | 59 | 39 | 77.2％ |
| Matched group (PIANTAN FUYUAN WAN) | 164 | 18 | 26 | 43 | 77 | 53％ |
The curative effect of treatment group as can be seen from Table 1 obviously is better than matched group (p＜0.01).
Claims (3)
1. a Chinese medicine preparation for the treatment of cerebral infarction sequela is characterized in that the Chinese medicine preparation of described treatment cerebral infarction sequela is made by following bulk drugs: 1～5 part of Radix Astragali, 1～3 part of Radix Salviae Miltiorrhizae, 0.5～1.5 part of Radix Angelicae Sinensis, 0.5～1.5 part of Rhizoma Chuanxiong, 1～3 part in Rhizoma Gastrodiae, 0.5～1.5 part of Cornu Saigae Tataricae, 1～3 part of Pheretima, 1～3 part of Radix Cyathulae, 1～3 part of Radix Paeoniae Rubra, 0.5～1.5 part of Ramulus Mori, 0.5～1.5 part of Radix Saposhnikoviae, 1～3 part of Herba Lycopodii, 1～3 part of Caulis Spatholobi, 1～3 part of Bombyx Batryticatus, 0.5～1.5 part of Rhizoma Typhonii, 0.5～1.5 part of Scorpio, 0.5～1.5 part of Squama Manis, 1～3 part of the Cortex Eucommiae, 0.5～1.5 part of Agkistrodon, 1～3 part of Carapax et Plastrum Testudinis, 1～3 part of Fructus Lycii, 1～3 part of Fructus Alpiniae Oxyphyllae, 1～3 part of Carapax Trionycis, 0.5～1.5 part in Radix Glycyrrhizae.
2. according to the Chinese medicine preparation of the described treatment cerebral infarction sequela of claim 1, it is characterized in that the Chinese medicine preparation of described treatment cerebral infarction sequela is made by following bulk drugs: 2～4 parts of Radix Astragali, 1.5～2 parts of Radix Salviae Miltiorrhizaes, 0.8～1.2 part of Radix Angelicae Sinensis, 0.8～1.2 part of Rhizoma Chuanxiong, 1.5～2 parts in Rhizoma Gastrodiae, 0.8～1.2 part of Cornu Saigae Tataricae, 1.5～2 parts of Pheretimas, 1.5～2 parts of Radix Cyathulaes, 1.5～2 parts of Radix Paeoniae Rubra, 0.8～1.2 part of Ramulus Mori, 0.8～1.2 part of Radix Saposhnikoviae, 1.5～2 parts of Herba Lycopodiis, 1.5～2 parts of Caulis Spatholobis, 1.5～2 parts of Bombyx Batryticatus, 0.8～1.2 part of Rhizoma Typhonii, 0.8～1.2 part of Scorpio, 0.8～1.2 part of Squama Manis, 1.5～2 parts of the Cortexs Eucommiae, 0.8～1.2 part of Agkistrodon, 1.5～2 parts of Carapax et Plastrum Testudiniss, 1.5～2 parts of Fructus Lycii, 1.5～2 parts of Fructus Alpiniae Oxyphyllaes, 1.5～2 parts of Carapax Trionycis, 0.8～1.2 part in Radix Glycyrrhizae.
3. according to the Chinese medicine preparation of the described treatment cerebral infarction sequela of claim 2, it is characterized in that the Chinese medicine preparation of described treatment cerebral infarction sequela is made by following bulk drugs: 3 parts of Radix Astragali, 2 parts of Radix Salviae Miltiorrhizaes, 1 part of Radix Angelicae Sinensis, 1 part of Rhizoma Chuanxiong, 2 parts in Rhizoma Gastrodiae, 1 part of Cornu Saigae Tataricae, 2 parts of Pheretimas, 2 parts of Radix Cyathulaes, 2 parts of Radix Paeoniae Rubra, 1 part of Ramulus Mori, 1 part of Radix Saposhnikoviae, 2 parts of Herba Lycopodiis, 2 parts of Caulis Spatholobis, 2 parts of Bombyx Batryticatus, 1 part of Rhizoma Typhonii, 1 part of Scorpio, 1 part of Squama Manis, 2 parts of the Cortexs Eucommiae, 1 part of Agkistrodon, 2 parts of Carapax et Plastrum Testudiniss, 2 parts of Fructus Lycii, 2 parts of Fructus Alpiniae Oxyphyllaes, 2 parts of Carapax Trionycis, 1 part in Radix Glycyrrhizae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102941016A CN101940751B (en) | 2010-09-28 | 2010-09-28 | Traditional Chinese medicinal preparation for treating sequela of cerebral infarction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102941016A CN101940751B (en) | 2010-09-28 | 2010-09-28 | Traditional Chinese medicinal preparation for treating sequela of cerebral infarction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101940751A CN101940751A (en) | 2011-01-12 |
| CN101940751B true CN101940751B (en) | 2011-09-28 |
Family
ID=43433081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102941016A Expired - Fee Related CN101940751B (en) | 2010-09-28 | 2010-09-28 | Traditional Chinese medicinal preparation for treating sequela of cerebral infarction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101940751B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083559A (en) * | 2013-01-10 | 2013-05-08 | 山东凤凰制药股份有限公司 | Novel preparation method and application of traditional Chinese medicine composition for treating cerebral infarction during acute stage and earlier restoration stage |
| CN103463466A (en) * | 2013-10-08 | 2013-12-25 | 黑君华 | Traditional Chinese medicine prescription for treating limb spasm in recovery phase and sequelae stage after cerebral infarction |
| CN103893441A (en) * | 2014-04-01 | 2014-07-02 | 徐跃萍 | Qianzheng plaster for treating hemiplegia |
| CN103893667B (en) * | 2014-04-18 | 2016-08-24 | 河北联合大学 | The Chinese medicine for the treatment of subacute combined degeneration of spinal cord disease and the preparation of compound dripping pill |
| CN104547431A (en) * | 2015-02-02 | 2015-04-29 | 刘勇 | Traditional Chinese medicine tablet for relieving cerebral infarction sequela and preparation method of traditional Chinese medicine tablet |
| CN105288241A (en) * | 2015-11-30 | 2016-02-03 | 闻喜县红十字会心脑血管病专科医院 | Traditional Chinese medicine for treating stroke, qi asthenia and blood stasis and preparation method of traditional Chinese medicine |
| CN105617039A (en) * | 2016-03-02 | 2016-06-01 | 罗维芳 | Traditional Chinese medicine composition for treating brain infarction and preparation method thereof |
| CN105687798A (en) * | 2016-03-22 | 2016-06-22 | 山东明人福瑞达卫生材料有限公司 | External traditional Chinese medicinal preparation for treating stroke and preparation method of external traditional Chinese medicinal preparation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1299672A (en) * | 1999-12-14 | 2001-06-20 | 王爱国 | Preparation of hemiplegia treating capsule |
| CN1415374A (en) * | 2002-11-08 | 2003-05-07 | 李素魁 | Chinese traditional medicine for curing diseases of cerebral hemorrhage, cerebral infarction and related sequela and its preparation method |
-
2010
- 2010-09-28 CN CN2010102941016A patent/CN101940751B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1299672A (en) * | 1999-12-14 | 2001-06-20 | 王爱国 | Preparation of hemiplegia treating capsule |
| CN1415374A (en) * | 2002-11-08 | 2003-05-07 | 李素魁 | Chinese traditional medicine for curing diseases of cerebral hemorrhage, cerebral infarction and related sequela and its preparation method |
Non-Patent Citations (2)
| Title |
|---|
| 张成智等.浅谈中风恢复期的中药治疗.《佳木斯医学院学报》.1997,第20卷(第2期),67-68. * |
| 路铁群.中风后遗症辨治体会.《实用中医内科杂志》.1996,第10卷(第3期),25-26. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101940751A (en) | 2011-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101940751B (en) | Traditional Chinese medicinal preparation for treating sequela of cerebral infarction | |
| CN101357175B (en) | Traditional Chinese medicine composition of foot soaking and massage | |
| CN102258591A (en) | Dampness eliminating, arthralgia relieving and meridian activating capsules | |
| CN103356854A (en) | Traditional Chinese medicine for treating rheumatism | |
| CN111840383A (en) | Targeted spray moxibustion composition for treating rheumatic arthritis and preparation and use methods thereof | |
| CN100998656A (en) | Medicated wine for tonifying bone and removing obstruction in channels | |
| CN101530568B (en) | Paralysis-expelling pain-relieving capsule | |
| CN100366278C (en) | Method for preparing traditional Chinese medicine for treating rheumatism and rheumatoid disease, and said medicine thereby | |
| CN103816402A (en) | Traditional Chinese medicine composition for treating liver wind agitation | |
| CN103356968B (en) | Traditional Chinese medicine composition for treating endometriosis | |
| CN102274457B (en) | Physiotherapy enhanced spray for scraping and massaging | |
| CN102406870B (en) | Medicament for treating rheumatic arthralgia | |
| CN101632745A (en) | Traditional Chinese medical compound preparation for treating rheumatism and rheumatoid arthritis | |
| CN101342245A (en) | Traditional Chinese medicine for treating rheumatism | |
| CN101700364B (en) | Thrombolytic and lipid-lowering pill | |
| CN103656588A (en) | Traditional Chinese medicine for auxiliary treatment of rheumatic arthritis | |
| CN102225118A (en) | Blood-activating wind-dispelling liquid | |
| CN101926880A (en) | Chinese medicinal composition for treating amenorrhea and endometritis of women | |
| CN101239140A (en) | Chinese medicine for treating psoriasis | |
| CN105770251A (en) | Tongning capsule for treatment of cervical spondylosis, lumbar diseases and arthritis | |
| CN101366934A (en) | Preparation method of pill for clearing and activating the channels and collaterals | |
| CN104288597A (en) | Traditional Chinese medicine composition for treating herpes zoster | |
| CN1515284A (en) | Rongshuan jiannaokang thrombolytic | |
| CN102988762A (en) | Plaster for treating traumatic fracture | |
| CN102258699A (en) | Chinese patent medicament for treating cervical spondylosis and cranial nerve vascular diseases and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: NANYANG INSTITUTE OF TECHNOLOGY Free format text: FORMER OWNER: SHI JINGYANG Effective date: 20110719 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20110719 Address after: 473000 Zhang Zhongjing Medical College, Nanyang Institute of Technology, 80 Changjiang Road, Henan, Nanyang Applicant after: Nanyang Science Technology College Address before: 473000 Zhang Zhongjing Medical College, Nanyang Institute of Technology, 80 Changjiang Road, Henan, Nanyang Applicant before: Shi Jingyang |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110928 Termination date: 20120928 |